CBLI Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Sep 2021 @ 06:00):

Stats
Tagesvolumen	116 255
Durchschnittsvolumen	156 953
Marktkapitalisierung	226.39M
EPS	$-0.0426 ( 2021-08-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.436 (13.75%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-27	Selsky Clifford	Buy	101 579	Common Stock, par value $0.005 per share
2021-07-27	Aronstam Peter	Buy	141 370	Common Stock, par value $0.005 per share
2021-07-27	Selsky Clifford	Buy	0
2021-07-27	Aronstam Peter	Buy	0
2021-07-27	Barbarick Steve K	Buy	0

INSIDER POWER
0.00
Last 91 transactions
Buy: 2 702 906 \| Sell: 404 086

Volumen Korrelation

Lang: 0.15 (neutral)

Kurz: -0.89 (strong negative)

Signal:(40.963) Neutral

Cleveland Biolabs Inc Korrelation

10 Am meisten positiv korreliert
HIBB	0.941
BEAT	0.933
HALO	0.926
BMRA	0.926
EMKR	0.925
VLCN	0.924
FNWD	0.912
PROV	0.911
GCBC	0.91
NDLS	0.909

10 Am meisten negativ korreliert
GPACU	-0.931
RXST	-0.928
MSAC	-0.926
TZPS	-0.925
KAII	-0.923
FRBN	-0.92
META	-0.919
MLAI	-0.919
ALPA	-0.916
AEAC	-0.916

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Cleveland Biolabs Inc Korrelation - Währung/Rohstoff

-0.22
( neutral )

-0.81
( strong negative )

0.00
( neutral )

-0.54
( weak negative )

-0.60
( weak negative )

0.12
( neutral )

Cleveland Biolabs Inc Finanzdaten

Annual	2020
Umsatz:	$262 942
Bruttogewinn:	$262.94 (0.10 %)
EPS:	$-0.190

FY	2020
Umsatz:	$262 942
Bruttogewinn:	$262.94 (0.10 %)
EPS:	$-0.190

FY	2019
Umsatz:	$1.11M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.230

FY	2018
Umsatz:	$1.14M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.320

Financial Reports:

No articles found.

Cleveland Biolabs Inc

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.